Bulletin
Investor Alert

Protagonist Therapeutics Inc.

NAS: PTGX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Protagonist Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 30, 2023, 7:56 p.m.

PTGX
/zigman2/quotes/205674595/composite

$

22.70

Change

+0.21 +0.93%

Volume

Volume 9,469

Quotes are delayed by 20 min

/zigman2/quotes/205674595/composite

Today's close

$ 22.34

$ 22.49

Change

+0.15 +0.67%

Day low

Day high

$22.10

$23.15

Open

52 week low

52 week high

$6.91

$25.76

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Protagonist Therapeutics Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20182019202020212022 5-year trend
Sales/Revenue 30.93M231,00028.63M27.36M26.58M
Cost of Goods Sold (COGS) incl. D&A ---2.78M1.03M
COGS excluding D&A -----
Depreciation & Amortization Expense 527,000703,000789,0002.78M1.03M
Depreciation 527,000703,000789,0002.78M1.03M
Amortization of Intangibles -----
Gross Income ---24.58M25.55M
20182019202020212022 5-year trend
SG&A Expense 72.67M82.75M93.86M153.53M156.92M
Research & Development 59.5M67.7M76.01M129.11M126.22M
Other SG&A 13.17M15.05M17.85M24.42M30.71M
Other Operating Expense -----
Unusual Expense --585,000--
EBIT after Unusual Expense --(66.6M)--
Non Operating Income/Expense -1.4M454,000(149,000)(80,000)
Non-Operating Interest Income 2.55M2.81M900,000443,0004.06M
Equity in Affiliates (Pretax) -----
Interest Expense -169,000598,000--
Gross Interest Expense -169,000598,000--
Interest Capitalized -----
Pretax Income (39.72M)(79.18M)(65.85M)(128.65M)(127.39M)
Income Tax (799,000)(1.99M)305,000(3.1M)-
Income Tax - Current Domestic -----
Income Tax - Current Foreign -84,000(88,000)--
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -(775,000)1.39M--
Income Tax Credits -1.3M1M3.1M-
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (38.92M)(77.19M)(66.15M)(125.55M)(127.39M)
Minority Interest Expense -----
Net Income (38.92M)(77.19M)(66.15M)(125.55M)(127.39M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (38.92M)(77.19M)(66.15M)(125.55M)(127.39M)
Preferred Dividends -----
Net Income Available to Common (38.92M)(77.19M)(66.15M)(125.55M)(127.39M)
EPS (Basic) (1.74)(2.98)(1.92)(2.71)(2.60)
Basic Shares Outstanding 22.36M25.89M34.4M46.32M49.04M
EPS (Diluted) (1.74)(2.98)(1.92)(2.71)(2.60)
Diluted Shares Outstanding 22.36M25.89M34.4M46.32M49.04M
EBITDA (41.74M)(82.52M)(65.23M)(126.17M)(130.34M)
Copyright 2023 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.